Vertex Pharma meets Q3 estimates, raises revenue guidance
Vertex Pharmaceuticals Inc (VRTX) delivered robust third quarter results that surpassed analyst expectations, maintaining full-year 2026 revenue guidance. Adjusted earnings per share of $4.76 met the consensus estimate, while revenue of $3.44 billion exceeded the $3.41 billion forecast. The company's broader pipeline advancements and Crinetics Pharmaceuticals acquisition contributed to its strong performance.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
